Skip to main content
. 2018 Jan 17;19(3):169–174. doi: 10.1080/15384047.2017.1414759

Figure 1.

Figure 1.

A: Kaplan-Meier survival curve of the PFS of the patients, who are treated with trastuzumab based treatment due to metastasized or recurrent upper-GI tumors. PFS was 11 months (7.8–14.1, 95% CI) among the whole cohort. 1B: Kaplan-Meier survival curve of the OS of the patients, who are treated with trastuzumab based treatment due to metastasized or recurrent upper-GI tumors. OS was 21 months (10.6–31.3, 95% CI) among the whole cohort.